Regulated health-science innovation, integrated into the cannabis platform.
BloomBridge Pharma connects the Group's cannabis heritage with medical research, clinical advisory relationships, genetic IP, pharmaceutical-grade production protocols, and regulated health-science opportunities. Activity is conducted only where supported by source material, licensed counterparties, and applicable approvals.
Where decades of cultivation meet evidence-based medicine.
Rooted in decades-long research, development, and innovation, BloomBridge Pharma is embedded in integrative technology and science. The Group maintains advisory and developmental relationships across medical cannabis, psychedelic-assisted therapy research, oncology cannabinoid research, and pediatric neurology — supporting clinical collaborations where regulatory frameworks allow.
Over the last operating cycle, the Group has extended into adjacent regulated markets where the same disciplines — licensing, provenance, compliance, and counterparty work — directly transfer. The health-science vertical connects BloomBridge's cannabis heritage with regulated pharma and health-science opportunities, clinical advisory relationships, genetic IP, evidence-based cannabis research, and compliance-grade documentation.
Therapeutic focus and research alignment.
Medical cannabis
Standardised cultivation protocols, cultivar verification, and pharmaceutical-grade production discipline carried forward from three decades of regulated-market work across California, Israel, the Czech Republic, and Australia.
Psychedelic-assisted therapy research
Advisory relationships under the Group's Chair of Research, in alignment with MAPS-affiliated regulated medical research and clinical study coordination across psychedelic-assisted therapies.
Oncology cannabinoid research
Aligned with cannabinoid-research laboratories advancing the therapeutic applications of cannabis bioactive compounds in oncology programmes.
Pediatric neurology
Clinical-study design under specialist pediatric-neurology supervision, with a focus on epilepsy and neurodevelopmental conditions.
Genetic IP & cultivar science
A substantial inventory of proprietary medical-grade cultivars supported by the Group's chief genetics and extractions office — a foundational discipline in cannabis breeding, extraction methodology, and cultivar development.
Precision gene therapy
Advisory input from gene-editing researchers whose work spans genome engineering tools with applications for CRISPR-based editing and cancer research.
Operating brands within the vertical.
Clinical, advisory, and research engagement.
Research collaborations, clinical-study design, and pharmaceutical-grade production engagement are conducted under NDA and reviewed by the Group's Medical & Research Board.